Breast Cancer Trial, Recruiting NCT07233928 Sponsor: Institut Claudius Regaud Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT07233928
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People (women or men) who have been diagnosed with breast cancer confirmed by a laboratory tissue test
  • People with either early-stage breast cancer or breast cancer that has spread to other parts of the body from the start (called de novo metastatic), of any breast cancer subtype — including Triple Negative, HER2-positive, Luminal A-like, or Luminal B-like breast cancer
  • People aged 18 or older at the time of joining the study
  • People currently being seen and treated through standard medical care or as part of another clinical trial
  • People with a reasonable level of physical functioning, meaning daily activities are not severely limited by illness (ECOG score of 2 or below — confirm with trial site if unsure what this means)
  • People whose breast cancer treatment has not yet begun
  • People who are willing and able to give written informed consent and follow the study procedures
  • People who are covered by the French national social health insurance system

Who may not be able to join:

  • People with a known history of Hepatitis B, Hepatitis C, HIV, or Hanta virus
  • People with blood clotting problems that would make having a biopsy unsafe
  • People who have already started or are currently receiving treatment for breast cancer
  • People whose breast cancer has spread only to the bones, with no other site available for a biopsy (applies to those with de novo metastatic breast cancer)
  • People with a health condition that makes blood draws unsafe, including those with a haemoglobin level below 8g/dl
  • People with another cancer that is currently growing or requires active treatment (some skin cancers and early-stage cervical cancer may be exceptions — confirm with trial site)
  • People who are pregnant or breastfeeding
  • People whose personal, psychological, family, geographic, or social circumstances may prevent them from giving informed consent or following the study procedures, based on the investigator's judgement
  • People who are under legal guardianship or whose freedom is restricted by an administrative or legal order

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +33 5311 55 104

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Institut Claudius Regaud
Registry
ClinicalTrials.gov
Start date
6 February 2026
Est. completion
6 February 2035

Where this trial is recruiting

🇫🇷 France

Primary endpoints

The amount of fatty acids accumulated in lipid droplets, quantified by the total intensity of a lipid-droplet specific fluorescent dye in the four cohorts

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov